Cingulate, Inc. (CING)
5.33
+0.14
(+2.70%)
USD |
NASDAQ |
Sep 09, 11:40
Cingulate Enterprise Value : 50.00M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 50.00M |
| September 04, 2026 | 48.75M |
| September 03, 2026 | 50.42M |
| September 02, 2026 | 49.45M |
| September 01, 2026 | 48.89M |
| August 31, 2026 | 49.72M |
| August 28, 2026 | 51.88M |
| August 27, 2026 | 53.48M |
| August 26, 2026 | 52.92M |
| August 25, 2026 | 59.45M |
| August 24, 2026 | 56.81M |
| August 21, 2026 | 55.00M |
| August 20, 2026 | 51.95M |
| August 19, 2026 | 51.11M |
| August 18, 2026 | 50.14M |
| August 17, 2026 | 50.28M |
| August 14, 2026 | 48.61M |
| August 13, 2026 | 47.22M |
| August 12, 2026 | 50.28M |
| August 11, 2026 | 50.14M |
| August 10, 2026 | 50.84M |
| August 07, 2026 | 52.09M |
| August 06, 2026 | 48.06M |
| August 05, 2026 | 46.53M |
| August 04, 2026 | 45.97M |
| Date | Value |
|---|---|
| August 03, 2026 | 45.00M |
| July 31, 2026 | 44.44M |
| July 30, 2026 | 44.03M |
| July 29, 2026 | 40.76M |
| July 28, 2026 | 40.83M |
| July 27, 2026 | 40.69M |
| July 24, 2026 | 42.36M |
| July 23, 2026 | 45.14M |
| July 22, 2026 | 45.14M |
| July 21, 2026 | 44.24M |
| July 20, 2026 | 41.25M |
| July 17, 2026 | 40.97M |
| July 16, 2026 | 39.44M |
| July 15, 2026 | 41.67M |
| July 14, 2026 | 43.33M |
| July 13, 2026 | 42.92M |
| July 10, 2026 | 46.11M |
| July 09, 2026 | 46.67M |
| July 08, 2026 | 45.14M |
| July 07, 2026 | 48.61M |
| July 06, 2026 | 51.53M |
| July 02, 2026 | 52.64M |
| July 01, 2026 | 59.73M |
| June 30, 2026 | 53.89M |
| June 29, 2026 | 44.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.848B |
| Corcept Therapeutics, Inc. | 12.00B |
| Veru, Inc. | 20.88M |
| Johnson & Johnson | 676.38B |
| Eli Lilly & Co. | 1.104T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.870M |
| Total Expenses (Quarterly) | 5.870M |
| EPS Diluted (Quarterly) | -0.4452 |
| Earnings Yield | -67.84% |
| Normalized Earnings Yield | -63.86 |